JP2020505425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505425A5 JP2020505425A5 JP2019541398A JP2019541398A JP2020505425A5 JP 2020505425 A5 JP2020505425 A5 JP 2020505425A5 JP 2019541398 A JP2019541398 A JP 2019541398A JP 2019541398 A JP2019541398 A JP 2019541398A JP 2020505425 A5 JP2020505425 A5 JP 2020505425A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- fgfr3
- eldaphytinib
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910019142 PO4 Inorganic materials 0.000 claims description 46
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 46
- 239000010452 phosphate Substances 0.000 claims description 46
- 210000002966 serum Anatomy 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 230000001394 metastastic effect Effects 0.000 claims description 10
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 47
- 230000002354 daily effect Effects 0.000 claims 11
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 10
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 10
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 8
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 8
- 101000836150 Homo sapiens Transforming acidic coiled-coil-containing protein 3 Proteins 0.000 claims 6
- 102100027048 Transforming acidic coiled-coil-containing protein 3 Human genes 0.000 claims 6
- 230000005945 translocation Effects 0.000 claims 6
- 101150025764 FGFR3 gene Proteins 0.000 claims 4
- 206010064571 Gene mutation Diseases 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 102200143272 rs121913479 Human genes 0.000 claims 4
- 102200143269 rs121913482 Human genes 0.000 claims 4
- 102200143266 rs121913483 Human genes 0.000 claims 4
- 102200143271 rs121913485 Human genes 0.000 claims 4
- 210000001635 urinary tract Anatomy 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102100024387 AF4/FMR2 family member 3 Human genes 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 102100028265 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 Human genes 0.000 claims 2
- 102100038902 Caspase-7 Human genes 0.000 claims 2
- 102100031048 Coiled-coil domain-containing protein 6 Human genes 0.000 claims 2
- 108091008794 FGF receptors Proteins 0.000 claims 2
- 101000833166 Homo sapiens AF4/FMR2 family member 3 Proteins 0.000 claims 2
- 101000935886 Homo sapiens Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 Proteins 0.000 claims 2
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 claims 2
- 101000777370 Homo sapiens Coiled-coil domain-containing protein 6 Proteins 0.000 claims 2
- 101000873646 Homo sapiens Protein bicaudal C homolog 1 Proteins 0.000 claims 2
- 102100035896 Protein bicaudal C homolog 1 Human genes 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000003203 everyday effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022189239A JP7668777B2 (ja) | 2017-02-06 | 2022-11-28 | 癌治療 |
| JP2024196985A JP2025024064A (ja) | 2017-02-06 | 2024-11-11 | 癌治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455211P | 2017-02-06 | 2017-02-06 | |
| US62/455,211 | 2017-02-06 | ||
| EP17209098 | 2017-12-20 | ||
| EP17209098.7 | 2017-12-20 | ||
| PCT/EP2018/052694 WO2018141921A1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022189239A Division JP7668777B2 (ja) | 2017-02-06 | 2022-11-28 | 癌治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505425A JP2020505425A (ja) | 2020-02-20 |
| JP2020505425A5 true JP2020505425A5 (enExample) | 2021-03-18 |
Family
ID=61094531
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541398A Withdrawn JP2020505425A (ja) | 2017-02-06 | 2018-02-02 | 癌治療 |
| JP2022189239A Active JP7668777B2 (ja) | 2017-02-06 | 2022-11-28 | 癌治療 |
| JP2024196985A Pending JP2025024064A (ja) | 2017-02-06 | 2024-11-11 | 癌治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022189239A Active JP7668777B2 (ja) | 2017-02-06 | 2022-11-28 | 癌治療 |
| JP2024196985A Pending JP2025024064A (ja) | 2017-02-06 | 2024-11-11 | 癌治療 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11077106B2 (enExample) |
| EP (2) | EP3576740B1 (enExample) |
| JP (3) | JP2020505425A (enExample) |
| KR (2) | KR20190110581A (enExample) |
| CN (1) | CN110198716A (enExample) |
| AU (2) | AU2018216969B2 (enExample) |
| BR (1) | BR112019016043A2 (enExample) |
| CA (1) | CA3049737A1 (enExample) |
| DK (1) | DK3576740T3 (enExample) |
| ES (1) | ES2953005T3 (enExample) |
| FI (1) | FI3576740T3 (enExample) |
| HR (1) | HRP20230697T1 (enExample) |
| HU (1) | HUE062453T2 (enExample) |
| IL (1) | IL268463A (enExample) |
| JO (1) | JOP20190190A1 (enExample) |
| LT (1) | LT3576740T (enExample) |
| MX (2) | MX2019009304A (enExample) |
| PH (1) | PH12019501885A1 (enExample) |
| PL (1) | PL3576740T3 (enExample) |
| RS (1) | RS64778B1 (enExample) |
| SG (2) | SG11201907199QA (enExample) |
| SI (1) | SI3576740T1 (enExample) |
| SM (1) | SMT202300233T1 (enExample) |
| TW (1) | TWI874925B (enExample) |
| UA (1) | UA126336C2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200208224A1 (en) * | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| MX392774B (es) | 2014-09-26 | 2025-03-24 | Janssen Pharmaceutica Nv | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr |
| JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
| AU2020223467B2 (en) * | 2019-02-12 | 2025-12-04 | Janssen Pharmaceutica Nv | Cancer treatment |
| PH12021552352A1 (en) * | 2019-03-29 | 2022-09-05 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| PH12021552342A1 (en) * | 2019-03-29 | 2022-08-22 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| CA3162962A1 (en) * | 2020-02-12 | 2021-08-19 | Manish MONGA | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| WO2021201201A1 (ja) * | 2020-04-03 | 2021-10-07 | インタープロテイン株式会社 | 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物 |
| WO2024241297A1 (en) * | 2023-05-24 | 2024-11-28 | Janssen Pharmaceutica Nv | Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200201A1 (ar) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
-
2017
- 2017-06-16 JO JOP/2019/0190A patent/JOP20190190A1/ar unknown
-
2018
- 2018-02-02 TW TW112109467A patent/TWI874925B/zh active
- 2018-02-02 EP EP18702299.1A patent/EP3576740B1/en active Active
- 2018-02-02 RS RS20230615A patent/RS64778B1/sr unknown
- 2018-02-02 SG SG11201907199QA patent/SG11201907199QA/en unknown
- 2018-02-02 UA UAA201909567A patent/UA126336C2/uk unknown
- 2018-02-02 DK DK18702299.1T patent/DK3576740T3/da active
- 2018-02-02 AU AU2018216969A patent/AU2018216969B2/en active Active
- 2018-02-02 HR HRP20230697TT patent/HRP20230697T1/hr unknown
- 2018-02-02 LT LTEPPCT/EP2018/052694T patent/LT3576740T/lt unknown
- 2018-02-02 SG SG10202105110VA patent/SG10202105110VA/en unknown
- 2018-02-02 US US16/483,579 patent/US11077106B2/en active Active
- 2018-02-02 CA CA3049737A patent/CA3049737A1/en active Pending
- 2018-02-02 FI FIEP18702299.1T patent/FI3576740T3/fi active
- 2018-02-02 MX MX2019009304A patent/MX2019009304A/es unknown
- 2018-02-02 KR KR1020197024552A patent/KR20190110581A/ko not_active Ceased
- 2018-02-02 SM SM20230233T patent/SMT202300233T1/it unknown
- 2018-02-02 ES ES18702299T patent/ES2953005T3/es active Active
- 2018-02-02 PL PL18702299.1T patent/PL3576740T3/pl unknown
- 2018-02-02 BR BR112019016043-4A patent/BR112019016043A2/pt not_active Application Discontinuation
- 2018-02-02 KR KR1020257014703A patent/KR20250069693A/ko active Pending
- 2018-02-02 CN CN201880008126.XA patent/CN110198716A/zh active Pending
- 2018-02-02 SI SI201830961T patent/SI3576740T1/sl unknown
- 2018-02-02 JP JP2019541398A patent/JP2020505425A/ja not_active Withdrawn
- 2018-02-02 HU HUE18702299A patent/HUE062453T2/hu unknown
- 2018-02-02 EP EP23178682.3A patent/EP4286005A3/en active Pending
-
2019
- 2019-08-04 IL IL268463A patent/IL268463A/en unknown
- 2019-08-05 PH PH12019501885A patent/PH12019501885A1/en unknown
- 2019-08-05 MX MX2022007955A patent/MX2022007955A/es unknown
-
2021
- 2021-06-28 US US17/360,618 patent/US20220110935A1/en not_active Abandoned
-
2022
- 2022-11-28 JP JP2022189239A patent/JP7668777B2/ja active Active
-
2024
- 2024-03-22 AU AU2024201871A patent/AU2024201871A1/en active Pending
- 2024-11-11 JP JP2024196985A patent/JP2025024064A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505425A5 (enExample) | ||
| Gbolahan et al. | A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma | |
| EP2863906B1 (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| JP2023113650A5 (enExample) | ||
| JP2019532051A5 (enExample) | ||
| JP2007515469A5 (enExample) | ||
| JP2013501224A5 (enExample) | ||
| CN110198716A (zh) | 癌症治疗 | |
| TWI468161B (zh) | 組合藥劑之醫藥產品、試劑及用途 | |
| TW202114691A (zh) | 惡性腫瘤之治療方法 | |
| Kohutek et al. | Optimal dose of silymarin for the management of drug‑induced liver injury in oncology | |
| Chu et al. | Management of chemotherapy dose intensity for metastatic colorectal cancer | |
| Suzuki et al. | Sustained-release lidocaine sheet for pain following tooth extraction: A randomized, single-blind, dose-response, controlled, clinical study of efficacy and safety | |
| WO2025167738A1 (zh) | 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用 | |
| CA3134156C (en) | Chiauranib for treatment of small cell lung cancer | |
| CN116265015A (zh) | 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及其用途 | |
| Chen et al. | Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients | |
| Lim et al. | HBsAg loss in inactive chronic hepatitis B carriers is dependent on level of qHBsAg and interferon response: a randomised control trial | |
| EP3127544A1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| Tolmane et al. | Original versus generic direct acting antivirals in treatment of chronic hepatitis C patients: Real life data from Latvia | |
| Rahnea-Nita et al. | Principles of Specific Treatment and Palliative Care in Advanced Head and Neck Cancer | |
| Pouliquen et al. | Optimization of cisplatin doses in a testicular cancer patient with acute renal failure | |
| JPWO2020165181A5 (enExample) | ||
| CN101342143A (zh) | 抗肿瘤药多西他赛注射液的制备工艺 | |
| Liu et al. | Low-dose apatinib in subjects with renal impairment: A pharmacokinetics study |